CD437

SKU: orb1302911

Description

CD437 (AHPN) is a synthetic retinoid that acts as a selective agonist for the Retinoic Acid Receptor γ (RARγ). It is widely used in research to study RARγ-mediated pathways in cellular differentiation, apoptosis, and proliferation, with applications in both in vitro and in vivo models of cancer and dermatology.

Research Area

Cell Biology, Metabolism Research

Key Properties

• CAS Number: 125316-60-1
• MW: 398.49
• Purity: 99.56%
• Formula: C₂₇H₂₆O₃
• SMILES: OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2
• Target: Autophagy,Retinoid Receptor
• Solubility: DMSO:127.5 mg/mL (319.96 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.02 mM)

Bioactivity

• In Vivo:
  CD437-treated mice exhibit tumor growth inhibition, with statistically significant effects (P<0.01) observed at days 3 and 13 post-administration, persisting for over three weeks after treatment cessation. Histologic analysis reveals elevated c-fos mRNA levels at the tumor-stroma interface in CD437-treated tumors.
• In Vitro:
  CD437 (10 μM, 2 days) inhibits the growth of these lung cancer cell lines. Dose-response experiments demonstrate that CD437 reduces the numbers of H460/SK-MES-1/A549/H292 cells (IC50: 0.5/0.4/3/0.85 μM). Treatment for 72 h with CD437 causes a strong dose-dependent growth inhibition in all melanoma cell lines. At a concentration of 5 μM CD437, only about 5 to 25% of the cells remain viable after 3 d. The concentrations of CD437 required for IC50 range from 10 μM for MeWo to 0.1 μM for SK-Mel-23 showing the highest sensitivity.
• Cell Research:
  For morphological analysis, cells are treated with 10 μM CD437, trypsinized, washed with phosphate-buffered saline (PBS), fixed with 3.7% paraformaldehyde, and stained with 50 μg of 4,6-diamidino-2-phenylindole (DAPI) per mL containing 100 μg of DNase-free RNase A per mL to visualize the nuclei. Stained cells are examined by fluorescence microscopy. For the terminal deoxynucleotidyl transferase (TdT) assay, cells are treated with or without 10 μM CD437. After treatment, cells are trypsinized, washed with PBS, fixed in 1% formaldehyde in PBS, washed with PBS, resuspended in 70% ice-cold ethanol, and immediately stored at -20°C overnight. Cells are then labeled with biotin-16-dUTP by terminal transferase and stained with avidin-FITC (fluorescein isothiocyanate).
• Animal Research:
  Male Swiss-nu/nu mice weighing 20 to 25 g are used in this study. Mice are kept under sterile conditions at 24 to 26°C room temperature, 50% relative humidity, and 12 h light-dark rhythm in laminar flow shelves and are supplied with autoclaved food and bedding. For treatment of melanoma xenografts, previously established MeWo melanoma tumors of 1 to 2 mm in diameter are implanted into the right flank of animals. After tumor growth for 10 d, groups of mice (n=8) are either treated with saline p.o. or are injected intratumorally for 3 wk or are fed with various concentrations of CD437 (10 mg/kg/body weight and 30 mg/kg/body weight). In addition, tumors of a fifth group are injected with CD437 (10 mg/kg/body weight) each day. Mice are visited daily and growing tumors are measured twice weekly with a caliperlike instrument.

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, O-Desmethyl Adapalene, Inhibitor, CD 437, CD-437, CD437, AHPN, Autophagy, Apoptosis Activator VI, Retinoic acid receptors, RetinoidReceptor, Retinoid Receptor, Retinoid X receptors, RAR/RXR, RARγ

Compound Identifiers

PubChem CID

135411